Clinical trials: Unspecified Adult Solid Tumor, Protocol Specific
Spinal Cord Compression, Unspecified Adult Solid Tumor, Protocol Specific
Spinal Cord Compression. ICORG 05-03, V6
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy schedule is more effective in treating patients with malignant spinal cord compression.
- Trial name
- NCT00968643
- Testing
- radiation therapy
- Where
- 4 sites in Ireland
- Volunteers
- 126 people
- Sponsor
- Cancer Trials Ireland
Unspecified Adult Solid Tumor, Protocol Specific
A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.
- Trial name
- NCT01358227
- Testing
- PR104
- Where
- 2 sites in New Zealand
- Volunteers
- 26 people
- Sponsor
- Proacta, Incorporated
Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Pemetrexed Disodium and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
RATIONALE: Pemetrexed disodium and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pemetrexed disodium together with erlotinib may kill more tumor cells.
- Trial name
- NCT00387322
- Testing
- erlotinib hydrochloride, pemetrexed disodium
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of California, Davis
Unspecified Adult Solid Tumor, Protocol Specific
BMS-599626 in Treating Patients With Metastatic Solid Tumors
RATIONALE: BMS-599626 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of BMS-599626 in treating patients with…
- Trial name
- NCT00093730
- Testing
- BMS-59926
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Unspecified Adult Solid Tumor, Protocol Specific, Non-Small Cell Lung Cancer
SORAVE - Sorafenib and Everolimus in Solid Tumors
Dose finding part: A phase I clinical trial to evaluate the safety of combined sorafenib and everolimus treatment in patients with relapsed solid tumors (finished).
- Trial name
- SORAVE (NCT00933777)
- Testing
- Combination of sorafenib and everolimus
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- University of Cologne
Unspecified Adult Solid Tumor, Protocol Specific
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer).
- Trial name
- NCT02215928
- Testing
- mutation analysis, cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Cachexia, Fatigue
Megestrol and Exercise in Treating Patients With Cancer-Related Weight Loss
RATIONALE: Megestrol helps improve appetite. Exercise may decrease cancer-related fatigue, improve strength, and build up lost muscle tissue. Exercise plus megestrol may be effective treatment for cancer-related weight loss.
- Conditions
- Cachexia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004912
- Testing
- megestrol acetate, physical therapy
- Where
- 6 sites in United States
- Sponsor
- Northwestern University
Breast Cancer, Colorectal Cancer
Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00667641
- Testing
- bortezomib, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat and gemcitabine in treating patients with metastatic or unresectable solid tumors.
- Trial name
- NCT00243100
- Testing
- vorinostat, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
RATIONALE: Extracranial stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00311597
- Testing
- Radiosurgery
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Wake Forest University Health Sciences
Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific
Quality of Life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers
RATIONALE: Studying quality-of-life in patients having cancer treatment and in their caregivers may help identify the intermediate- and long-term effects of treatment on patients with cancer and on their caregivers.
- Trial name
- NCT00255697
- Testing
- psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 863 people
- Sponsor
- Case Comprehensive Cancer Center
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients being treated with chemotherapy. PURPOSE: This randomized phase III trial is comparing how well different antiemetic drugs work in…
- Trial name
- NCT00020657
- Testing
- dolasetron mesylate, granisetron hydrochloride, ondansetron
- Where
- 15 sites in United States
- Sponsor
- Gary Morrow
Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Methylphenidate in Treating Patients With Fatigue Caused by Cancer
RATIONALE: Methylphenidate may help relieve fatigue caused by cancer. It is not yet known whether methylphenidate is more effective than a placebo in relieving fatigue and improving quality of life in patients with cancer.
- Trial name
- NCT00376675
- Testing
- methylphenidate hydrochloride
- Where
- 238 sites in United States
- Volunteers
- 148 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma
Drugs used in chemotherapy such as gemcitabine use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00060112
- Testing
- oblimersen sodium, gemcitabine hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
EF5 in Treating Patients With Solid Tumors
Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells may help to plan effective treatment for solid tumors.
- Trial name
- NCT00003282
- Testing
- EF5, therapeutic conventional surgery, biopsy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers
A phase I study is conducted to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), safety and pharmacokinetics (PK) profile of a single agent CKD-516 injection on twice-weekly schedule in patients with…
- Trial name
- NCT01560325
- Testing
- CKD-516 inj.
- Where
- South Korea
- Volunteers
- 21 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Unspecified Adult Solid Tumor, Protocol Specific
Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors
This phase I trial is studying the side effects and best dose of vorinostat when given together with alvocidib in treating patients with advanced solid tumors.
- Trial name
- NCT00324480
- Testing
- alvocidib, vorinostat, pharmacological study
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
The purpose of this study is to determine the dose of smac mimetic TL32711 that is safe and tolerated when given with gemcitabine hydrochloride to patients with advanced cancer
- Trial name
- NCT01573780
- Testing
- Smac mimetic TL32711, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Roswell Park Cancer Institute
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics